Clinical Trial Update: A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update concerns a Phase I/II study evaluating HCB101 in combination with pembrolizumab for platinum-refractory, recurrent or metastatic head…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• HCB101 (HCB101)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: HNSCC | Phase 1, Phase 2 | Status: RECRUITING